1. Home
  2. EML vs STTK Comparison

EML vs STTK Comparison

Compare EML & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastern Company (The)

EML

Eastern Company (The)

HOLD

Current Price

$19.90

Market Cap

130.2M

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.09

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EML
STTK
Founded
1858
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
130.2M
119.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
EML
STTK
Price
$19.90
$3.09
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$4.00
AVG Volume (30 Days)
10.5K
328.1K
Earning Date
11-04-2025
11-06-2025
Dividend Yield
2.18%
N/A
EPS Growth
N/A
N/A
EPS
1.19
N/A
Revenue
$258,121,226.00
$1,000,000.00
Revenue This Year
$1.56
N/A
Revenue Next Year
$7.00
N/A
P/E Ratio
$19.53
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.49
$0.69
52 Week High
$30.72
$3.38

Technical Indicators

Market Signals
Indicator
EML
STTK
Relative Strength Index (RSI) 49.47 68.57
Support Level $19.73 $1.93
Resistance Level $20.86 $3.30
Average True Range (ATR) 0.65 0.24
MACD 0.19 0.06
Stochastic Oscillator 53.66 77.24

Price Performance

Historical Comparison
EML
STTK

About EML Eastern Company (The)

The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: